The Progression of Alzheimer's: From Subtle Beginnings to Swift Decline

Researchers have discovered that a particular neuron type is impacted early in the development of Alzheimer's disease.

An analysis conducted on cellular samples from 84 brain donors reveals that Alzheimer's disease unfolds in two key stages, with a specific class of neurons being notably susceptible.

"Initially, there's a gradual buildup of pathological signs," explains a key researcher from the Allen Institute for Brain Science in Seattle, "followed by a phase where these signs proliferate rapidly, marking severe disease escalation."

The study identified that a minor group of neurons begins to perish during the early Alzheimer's phase, as reported by Lein and nearly 100 colleagues in a scientific journal.

Lein comments, "This finding was unexpected, particularly because these neurons have rarely been the focus of Alzheimer’s research until now."

These findings indicate that treatments for Alzheimer's are most effective in its initial stages, suggesting that fortifying the vulnerable inhibitory neurons could be beneficial.

The study also details how cutting-edge tools and methods give scientists unprecedented insights into the individualized cells within the brain.

"This research provides a novel perspective on the disease's progression that wasn't conceivable a few years back," states the director of the National Institute on Aging, a major supporter of the study.

Understanding Neuronal Transformations

The study examined over 3.4 million brain cells from individuals aged 65 and older, including those with healthy minds and those at varying Alzheimer's stages.

Attention was concentrated on the middle temporal gyrus, an area essential for language, memory, and vision.

By contrasting cells across different Alzheimer's phases, scientists could chart the disorder's impact on brain structure.

"We analyze the full genome of each cell," Lein expresses. "This allows for both cell identification and recognition of the disease-induced changes."

Certain discoveries confirmed past studies, such as the heightened activity in brain cells involved in immune responses.

Lein notes that through the application of AI and advanced imaging and genetic techniques, the research could uncover transformations previously unnoticed.

"Our aim was to identify vulnerable neuron subtypes, especially those more likely to be depleted early in the disease," Lein mentions.

Originally, scientists anticipated changes in excitatory neurons, which extend to distant brain areas acting as accelerators by promoting neuronal firing.

However, Lein clarifies that it is the inhibitory neurons that are predominantly first affected.

Inhibitory neurons, functioning as neuronal brakes, form connections with nearby excitatory neurons to regulate their activity.

These specific inhibitory neurons diminish early in Alzheimer's and are responsible for releasing somatostatin, a chemical messenger known to decrease in Alzheimer's sufferers.

Somatostatin neurons are crucial for maintaining the function of neural networks vital to memory and cognitive processes.

A decrease in these neurons can disturb the balance between inhibitory and excitatory neurons, potentially contributing to conditions like epilepsy and other neurological disorders.

"The loss of these [somatostatin] inhibitory neurons may incite an overly excited neural state, exacerbating the disease," Hodes suggests.

Should this prove accurate, Hodes insists interventions should commence before extensive inhibitory neuron loss occurs, a possibility supported by the study.

"The slow progression in early stages provides a strategic window for early intervention," he concludes.